Merck & Co., Inc. (NYSE:MRK) Announces Dividend Increase – $0.88 Per Share

Merck & Co., Inc. (NYSE:MRK – Get Free Report) announced a quarterly dividend on Tuesday, November 17th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.88 per share on Friday, January 8th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Tuesday, December 15th. This is a 3.5% increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85.

Merck & Co., Inc. has increased its dividend payment by an average of 0.1% annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Merck & Co., Inc. has a payout ratio of 35.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Merck & Co., Inc. to earn $9.08 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 37.4%.

Merck & Co., Inc. Stock Down 1.0%

NYSE MRK opened at $143.01 on Wednesday. Merck & Co., Inc. has a 52 week low of $92.11 and a 52 week high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. The business’s fifty day simple moving average is $145.93 and its 200-day simple moving average is $128.97. The firm has a market cap of $352.56 billion, a PE ratio of 147.43, a P/E/G ratio of 6.62 and a beta of 0.13.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The firm had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter in the previous year, the company posted $2.58 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current year.

Key Stories Impacting Merck & Co., Inc.

Investors following MRK have been watching these stories:

  • Positive Sentiment: Goldman Sachs reportedly raised its price target to $165 from $155 and maintained a Buy rating, signaling continued analyst optimism. Goldman Sachs Raises Its Merck Target to $165
  • Neutral Sentiment: Director Thomas H. Glocer plans to retire in May 2027, and Douglas M. Baker, Jr. has been appointed independent lead director. The planned board transition does not indicate an immediate change to operations. Merck Board of Directors Announcement
  • Negative Sentiment: Merck discontinued the BELLWAVE clinical program for nemtabrutinib, an investigational drug for CLL, SLL and other blood cancers, following a risk assessment. Ending the program removes a potential pipeline opportunity. Merck Stops Trials of Blood Cancer Drug After Risk Assessment

About Merck & Co., Inc.

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Recommended Stories

Dividend History for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.